GlassScriptPhysician profile
Meredith B Graham
NPI 1912422163
$4,656.96
in general payments reported to CMS, 2019-2025
52 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $624 · 2023: $659 · 2024: $1,522 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,572 · Education: $85.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,572.06 |
| Education | $85.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $359.97 | 2022-2025 | Carvykti, Imbruvica, Tecvayli |
| Celgene Corporation | $270.27 | 2021-2025 | Reblozyl, Pomalyst, Breyanzi |
| Astrazeneca Pharmaceuticals LP | $270.19 | 2021-2025 | Calquence, Tagrisso, Imfinzi |
| Incyte Corporation | $264.73 | 2024-2025 | Monjuvi, Zynyz, Jakafi |
| Abbvie INC. | $232.01 | 2022-2025 | |
| Genentech USA, INC. | $228.74 | 2021-2025 | Polivy, Lunsumio, Perjeta |
| Merck Sharp & Dohme LLC | $210.26 | 2022-2025 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $203.74 | 2023-2025 | |
| Daiichi Sankyo INC. | $200.73 | 2022-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $183.84 | 2021-2025 | Ninlaro, Iclusig |
| Aveo Pharmaceuticals, INC. | $170.42 | 2022-2025 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $135.34 | 2021-2025 | Opdivo, Krazati, Augtyro |
| Beigene USA, INC. | $121.47 | 2021-2024 | Brukinsa, Tevimbra |
| Puma Biotechnology, INC. | $118.91 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.48 | 2022-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $100.23 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $100.20 | 2021-2025 | Ultomiris |
| Emd Serono, INC. | $94.44 | 2024-2025 | |
| Lilly USA, LLC | $93.87 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $89.25 | 2024-2025 | |
| Glaxosmithkline, LLC. | $84.04 | 2021-2023 | Jemperli |
| Karyopharm Therapeutics INC. | $72.61 | 2022-2025 | Xpovio |
| Exelixis INC. | $69.03 | 2021-2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $68.99 | 2022-2025 | Qinlock, Romvimza |
| Beone Medicines USA, INC. | $67.34 | 2025 | Brukinsa, Tevimbra |
| Jazz Pharmaceuticals INC. | $53.97 | 2021-2025 | |
| Astellas Pharma US INC | $52.89 | 2023-2024 | Padcev |
| Pharmacosmos Therapeutics INC. | $45.14 | 2021-2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $39.02 | 2021-2023 | Libtayo |
| Acceleron Pharma, INC. | $38.67 | 2021 | |
| Rigel Pharmaceuticals, INC. | $38.41 | 2023 | Tavalisse, Rezlidhia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.07 | 2021-2024 | Gilotrif |
| Caris Mpi, INC. | $32.91 | 2025 | Mi Cancer Seek |
| Alnylam Pharmaceuticals INC. | $32.54 | 2022-2023 | Amvuttra |
| Seagen INC. | $32.43 | 2021-2022 | |
| Morphosys, US INC. | $30.55 | 2022-2023 | Monjuvi |
| Springworks Therapeutics, INC. | $30.52 | 2024 | Ogsiveo |
| Myriad Genetic Laboratories, INC. | $29.64 | 2021-2024 | Precisetumor |
| Pharmacyclics LLC, An Abbvie Company | $29.12 | 2022-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $28.33 | 2025 | |
| Macrogenics, INC. | $23.24 | 2022 | |
| Ferring Pharmaceuticals INC. | $22.56 | 2025 | Adstiladrin |
| Boston Scientific Corporation | $19.74 | 2024 | Spaceoar Vue System - 10ml |
| Adc Therapeutics America, INC. | $18.52 | 2025 | |
| Blueprint Medicines Corporation | $15.91 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.51 | 2024 | |
| Coherus Oncology, INC. | $14.04 | 2021 | |
| Aadi Bioscience, INC. | $14.02 | 2023 | Fyarro |
| Foundation Medicine, INC. | $13.40 | 2021 | |
| Kyowa Kirin, INC. | $12.76 | 2022 | |
| Taiho Oncology, INC. | $12.04 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.